This document discusses opioid induced hyperalgesia (OIH), where increased pain results from opioid use. OIH is caused by changes in the glutaminergic and descending pain pathways in the central nervous system. Patients at risk include those on long-term opioids, perioperative opioid use, and acute opioid administration. OIH presents as diffuse pain not explained by the original condition and increases with higher opioid doses. Management focuses on tapering opioids while adding adjuvant medications targeting NMDA receptors or other pain mechanisms to modulate OIH. A multidisciplinary approach is needed given the complex pathophysiology.